We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$647M
AUM Growth
-$194M
Cap. Flow
-$64.4M
Cap. Flow %
-9.95%
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$20.4M
2
NKTR icon
Nektar Therapeutics
NKTR
+$14.1M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$8.7M
4
ESPR
Esperion Therapeutics
ESPR
+$6.56M
5
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
+$4.27M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12M
2
BIIB icon
Biogen
BIIB
+$8.66M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$3.63M
4
COGT icon
Cogent Biosciences
COGT
+$3.16M
5
INCY icon
Incyte
INCY
+$2.77M

Sector Composition

Rank Sector Weight
1 Healthcare 26.13%
2 Consumer Staples 0.17%
3 Financials 0.05%
4 Industrials 0.05%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLS icon
176
CALL
SELLAS Life Sciences
SLS
$1.99B
– –
-30
Closed -$4K
SLS icon
177
SELLAS Life Sciences
SLS
$1.99B
– –
-6,184
Closed -$1.07M
SNES icon
178
SenesTech
SNES
$6.74M
– –
-17
Closed -$405K
SNOA icon
179
Sonoma Pharmaceuticals
SNOA
$5.26M
– –
-384
Closed -$255K
SPY icon
180
State Street SPDR S&P 500 ETF Trust
SPY
$771B
– –
-44,500
Closed -$12M
VNRX icon
181
VolitionRx Ltd
VNRX
$9.31M
– –
-658
Closed -$32K
VRTX icon
182
CALL
Vertex Pharmaceuticals
VRTX
$123B
– –
-1,315
Closed -$861K
VTGN icon
183
VistaGen Therapeutics
VTGN
$9.98M
– –
-4,783
Closed -$133K
XENE icon
184
Xenon Pharmaceuticals
XENE
$6.1B
– –
-67,000
Closed -$328K
XYLO
185
DELISTED
Xylo Technologies
XYLO
– –
-148
Closed -$30K
SEEL
186
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-16
Closed -$731K
ASXC
187
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-19,747
Closed -$436K
ASXC
188
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-56
Closed -$124K
EIGR
189
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,073
Closed -$317K
BPTH
190
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-213
Closed -$170K
IMGN
191
PUT
DELISTED
Immunogen Inc
IMGN
– –
-164
Closed -$173K
ARAV
192
CALL
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-33
Closed -$3K
FRTX
193
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-190
Closed -$87K
XLRN
194
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-55
Closed -$215K
XLRN
195
DELISTED
Acceleron Pharma
XLRN
– –
-8,646
Closed -$338K
XLRN
196
PUT
DELISTED
Acceleron Pharma
XLRN
– –
-524
Closed -$2.05M
ALXN
197
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-593
Closed -$6.61M
ALXN
198
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-96
Closed -$1.07M
BNTCW
199
CALL
DELISTED
Benitec Biopharma Limited
BNTCW
– –
-87,693
Closed -$21K
ADOM
200
DELISTED
ADOMANI Inc
ADOM
– –
-843,407
Closed -$995K
5 6 7
8
9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management withdrew a net $64.4M in Q2 2018, closing 71 positions and reducing 42 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 16% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Novo Nordisk worth $19.8M.

  • Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
  • Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
  • Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
  • Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
  • Sabby Management opened 51 new positions and closed 71 in Q2 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.